Search
Quell Tx believes that restoring immune balance rather than entirely depleting cells is key for many autoimmune conditions - a phase 1/2 for its CAR-Treg initiated today in RA & Systemic Sclerosis
CEO Iain McGill describes the "Chill, not Kill" approach that Quell is taking with its Treg platform, which integrates a FOXP3 phenotype lock in addition to the CAR. Plus, an update on the company's liver transplant study, a program that he says will need a partner to move forward.
Mar 3
Quell Therapeutics' CEO describes the process of using genetically modified Tregs for immune dysregulation conditions
Iain McGill discusses the company's clinical liver transplant program, as well as IBD and type 1 diabetes programs.
Apr 29, 2024
.png){kind=logo}
